Hello and welcome to the details of Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy and now with the details
Nevin Al Sukari - Sana'a - Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market such as Ozempic. — Reuters pic
LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25 per cent weight loss.
Martin Holst Lange, Novo Nordisk’s head of development, made the comments to Reuters in an interview after the company released better-than-expected third-quarter results.
The Danish drugmaker is due to release data from a late-stage trial of CagriSema, a two-drug combination obesity treatment that like its popular obesity drug Wegovy is injected, by the end of 2024. — Reuters
These were the details of the news Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
